Abstract 428 Figure 2

sequelae. Compared with controls of 130 SLE patients without HZ, cases were significantly more likely to have received high-dose prednisone 65/65 (OR 16.41, $p=0.0066$) with mean prednisone 18.5 ± 12 mg/day and cyclophosphamide (Cyc) 19/65 (OR 7.05, $p<0.0001$). IV Cyc with mycophenolate mofetil (MMF) conferred greatest risk for HZ infection. There was no association of disease activity with HZ risk, whereas hydroxychloroquine was a negative risk factor for HZ infection (OR 0.26, $p=0.0005$).

Conclusions Immunosuppressive agents and corticosteroids are risk factors associated with development of HZ in SLE. On the other hand, hydroxychloroquine appeared to have a protective role against HZ.

431 A MULTICENTER STUDY OF CLINICAL FEATURES AND REMISSION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN CHINA

C Zhao*. Peking University People's Hospital, Department of Rheumatology and Immunology, Beijing, China

10.1136/lupus-2017-000215.431

Background and aims To study the clinical characteristics and remission rate in systemic lupus erythematosus (SLE), and to investigate potential factors affecting remission. These data may provide evidence for rational medication of SLE.

Methods Clinical remission was defined as follows: SLEDAI ≤ 4 , with no SLEDAI activity in major organ systems (renal, central nervous system, cardiopulmonary, vasculitis, hemolytic anaemia, fever) and no gastrointestinal activity; Current prednisone (or equivalent) dose ≤ 7.5 mg daily; Well-tolerated standard maintenance doses of immunosuppressive drugs, hydroxychloroquine, and/or approved biologic agents. A cross-sectional survey was undertaken in 11 hospitals of China from October 2013 to April 2014. Clinical data of 485 consecutive SLE patients were collected.

Results 1. A total of 82 patients (17.5%) achieved clinical remission. Patients who received hydroxychloroquine or immunosuppressant therapy for more than 6 months yielded a higher remission rate of 24.0% (69/288). 2. The factors, including gender, age, marriage, education background, work environment, income and history of autoimmune diseases, had no significant correlations with the remission of SLE. 3. There are 51.3% of the patients with SLEDAI ≤ 4 . And 59.8% patients complained of symptoms, the most often symptoms were alopecia, Raynaud's phenomenon and arthritis. Anti-nuclear Antibody, anti-dsDNA, and hypocomplementaemia

were common seen in SLE patients. 4. Most SLE patients received small doses of glucocorticoid. Hydroxychloroquine is a common choice in the SLE therapeutics in China.

Conclusions The clinical remission among SLE patients is infrequent. Half of the patients are in a stable state. In order to target remission, prevent damage and improve quality of life, treating-to-target-in-SLE should be recommended.

432 PERICARDIAL EFFUSION AND CARDIAC TAMPONADE IN SYSTEMIC LUPUS ERYTHEMATOSUS

¹YF Chen*, ²KH Yu. ¹Taipei, Taiwan R.O.C; ²Chang Gung Memorial Hospital- and- Chang Gung University, Division of Rheumatology- Allergy and Immunology- Department of Internal Medicine-, Tao-yuan, Taiwan R.O.C

10.1136/lupus-2017-000215.432

Background and aims To investigate the factors associated with systemic lupus erythematosus (SLE)-related pericardial effusion/ cardiac tamponade and its long-term outcome in Chinese patients.

Methods Medical records of 690 SLE patients who admitted in Chang Gung Medical Centre from 2005 to 2012 were reviewed.

Results The mean ages at onset and at admission were 36.3 ± 16.4 years and 40.8 ± 16.0 years, respectively. Of the 690 patients, 113 (16.4%) had SLE-related pericardial effusion. Cardiac tamponade developed in 9.7% (11 of 113) patients with pericardial effusion or in 1.5% (11 of 690) of SLE patients. Moreover, 4 of the 11 patients represented with cardiac tamponade as initial presentation of SLE. Cox regression analysis indicated that age at admission >50 years (HR 3.38, 95% CI 2.06–5.55, $p<0.001$), pericarditis (HR 1.70, 95% CI 1.00–2.90, $p=0.049$), pleuritis (HR 2.30, 95% CI 1.43–3.72, $p=0.001$), leukopenia (HR 1.90, 95% CI 1.11–3.24, $p=0.019$), thrombocytopenia (HR 3.28, 95% CI 1.82–5.89, $p<0.001$), and seizure (HR 1.84, 95% CI 1.12–3.00, $p=0.016$) were associated with mortality in SLE. The mortality rate was higher in the pericardial effusion group (30.1%; 34/113) than in the non-pericardial effusion group (11.3%;

Abstract 432 Figure 1

65/577; $p < 0.001$) The cumulative survival rate of the non-pericardial effusion group was 96.9%, 95.8%, 93.6%, and 87.1% at 1 year, 2 years, 5 years and 10 years; which were 89.0%, 86.0%, 78.4%, and 69.6%, respectively, in the pericardial effusion group.

Conclusions This study underlines the prevalence and outcome of pericardial

effusion/cardiac tamponade in SLE, which is significant related to patient survival.

433

LATE-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS IN CHINESE PATIENTS REVEALS A NON-BENIGN DISEASE

Z Chen*, GS Wang, XP Li, XM Li. *Affiliated Anhui Provincial Hospital – Anhui Medical University, Rheumatology and Immunology, Hefei, China*

10.1136/lupus-2017-000215.433

Background and aims To assess clinical manifestations, laboratory findings and outcome of a cohort of Chinese SLE patients with onset at age ≥ 50 from a tertiary referral centre by performing a case control study.

Methods All hospitalised SLE patients in last five years were retrospectively reviewed. Patients who developed disease at or after the age of 50 were considered as LOSLE. 1:1 matched control SLE patients, admitted in the same period with initial symptoms onset before the age of 50, paired by race and disease duration, were randomly selected. Clinical manifestations, laboratory findings, therapies as well as outcome of the two groups of patients were compared.

Results LOSLE amounts to 4.3% (35/814) of all SLE patients in our centre. The most frequent clinical manifestations of LOSLE were arthralgia (60%), fever (37.1%) and serositis (37.1%). Compared with younger onset patients, LOSLE had less incidence of rash, oral ulcers, Raynaud's phenomenon, but had more renal involvement and secondary sjogren's syndrome. In laboratory findings, positive anti-dsDNA, anti-Sm, anti-SSA, anti-SSB and anti-RNP antibody were less frequent in LOSLE compared with younger SLE patients. Additionally, SLEDAI was lower in LOSLE group at diagnosis and fewer LOSLE patients received cytotoxic agents. However, one -year survival rate was lower in LOSLE group than control patients (78% and 91%, respectively).

Conclusions Patients of LOSLE tend to be milder and atypical in symptoms, signs and laboratory findings, but they are prone to experience more severe renal damage and higher mortality. LOSLE appear to be a non-benign disease in our cohort of Chinese patients.

434

GOING DOWN A DIFFERENT PATH": A QUALITATIVE EXPLORATION OF COSTS INCURRED BY CANADIAN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

¹J Dixon, ¹S Elliott, ²S Pike, ³C Seger*, ³R Church, ⁴A Clarke. ¹University of Waterloo, Geography and Environmental Management, Waterloo, Canada; ²McGill University, Montreal, Canada; ³Lupus Society of Alberta, Calgary, Canada; ⁴University of Calgary, Department of Medicine Division of Rheumatology Cumming School of Medicine, Calgary, Canada

10.1136/lupus-2017-000215.434

Background and aims Prior investigations into the economic costs of Systemic Lupus Erythematosus (SLE) among affected

individuals have primarily been quantitative and focused only on direct costs. Given that SLE predominantly impacts patients during their prime working years and symptoms can be complex, this research employs a qualitative approach to explore and contextualise the direct as well as indirect costs incurred by Canadian patients with SLE.

Methods Semi structured in-depth interviews were conducted with 8 key informants (3 expert physicians, 5 representatives from patient advocacy groups) and 28 adult SLE patients. Interviews were audio recorded, transcribed verbatim and coded for recurring themes.

Results Findings reveal that the early manifestations of the disease significantly rerouted the course of participants' economic livelihoods, often to part-time precarious employment and in some cases forced them to leave the workforce all together. A lack of health insurance benefits and poor health coverage for complementary care created additional expenses. Openness about diagnosis within the workplace varied greatly amongst participants, though all noted the challenges created by a general lack of information and public awareness about SLE. The use of workplace accommodations was met with mixed success and greatly depended on the work setting.

Conclusions Changes within Canadian policy could improve access to resources for promoting healthy lifestyles and disease management for those with SLE which, in turn, would serve to enhance economic security. This research adds deeper understanding to the widespread and multifaceted costs associated with SLE, elucidating the long-term consequences of SLE and its implications for social policy.

435

DISEASE ACTIVITY PATTERNS AMONG FILIPINO PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A 3-YEAR OBSERVATIONAL STUDY

MFJ Edar, L Zamora, S Navarra. *University of Santo Tomas, Internal Medicine, Manila, Philippines*

10.1136/lupus-2017-000215.435

Background and aims To describe organ involvement, disease activity patterns, and damage characteristics in a cohort of Filipino patients with systemic lupus erythematosus (SLE), observed over 3 years.

Methods Consenting SLE patients at University of Santo Tomas (UST) Hospital with minimum 3 visits/year were assessed over 3 years until July 2016. Disease activity patterns included clinically quiescent disease (CQD; SLEDAI=0 in 3 visits); minimal persistent disease (MDA; SLEDAI=1 in >1 visit); relapsing remitting disease (RRD; SLEDAI ≥ 2 in 1 of 3 visits); chronic active disease (CAD; SLEDAI ≥ 2 in at least 2 of 3 visits). SLICC Damage Index (SDI) characteristics were correlated with steroid use.

Results 127 SLE patients (117, 92% females), mean 28.81 ± 10.14 SD (range 4–57) age at diagnosis, mean 7.94 ± 5.61 SD (range 1–25) years disease duration. Organ involvement included mucocutaneous (121, 95%), musculoskeletal (113, 89%) and renal (87, 68.5%). At 1 year there were 48 (40.7%) patients with CAD, 37 (31.4%) CQD, 30 (25.4%) RRD, 3 (2.5%) MDA. At 3 years, CAD patients totaled 23 (19.5%), CQD 59 (50%). Table 1 Mean cumulative prednisone dose was 21.42 ± 17.63 at initial damage involvement. Cataract was most common SDI (26, 20.5%), significantly correlated with cumulative steroid, $p < 0.01$. There were 131